Precise excision of HTLV-1 provirus with a designer-recombinase
Molecular Therapy · 2023-07 · 31 (7) · 2266-2285
DOI: 10.1016/j.ymthe.2023.03.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2023-07. Verfasst von Teresa Rojo-Romanos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Systems Biology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, Paraparesis, Tropical Spastic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission, European Research Council, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
The human T cell leukemia virus type 1 (HTLV-1) is a pathogenic retrovirus that persists as a provirus in the genome of infected cells and can lead to adult T cell leukemia (ATL). Worldwide, more than 10 million people are infected and approximately 5% of these individuals will develop ATL, a highly aggressive cancer that is currently incurable. In the last years, genome editing tools have emerged as promising antiviral agents. In this proof-of-concept study, we use substrate-linked directed evolution (SLiDE) to engineer Cre-derived site-specific recombinases to excise the HTLV-1 proviral genome from infected cells. We identified a conserved loxP-like sequence (loxHTLV) present in the long terminal repeats of the majority of virus isolates. After 181 cycles of SLiDE, we isolated a designer-recombinase (designated RecHTLV), which efficiently recombines the loxHTLV sequence in bacteria and human cells with high specificity. Expression of RecHTLV in human Jurkat T cells resulted in antiviral activity when challenged with an HTLV-1 infection. Moreover, expression of RecHTLV in chronically infected SP cells led to the excision of HTLV-1 proviral DNA. Our data suggest that recombinase-mediated excision of the HTLV-1 provirus represents a promising approach to reduce proviral load in HTLV-1-infected individuals, potentially preventing the development of HTLV-1-associated diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Systems Biology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany.
- Institute of Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
- PROVIREX Genome Editing Therapies GmbH, Luruper Hauptstrasse 1, 22547 Hamburg, Germany.
- Medical Systems Biology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany. Electronic address: frank.buchholz@tu-dresden.de.
Förderung
- European Commission
- European Research Council
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- BMBF Berlin
Zitieren
APA
Rojo-Romanos, T., Karpinski, J., Millen, S., Beschorner, N., Simon, F., Paszkowski-Rogacz, M., Lansing, F., Schneider, P. M., Sonntag, J., Hauber, J., Thoma-Kress, A. K., & Buchholz, F. (2023). Precise excision of HTLV-1 provirus with a designer-recombinase. Molecular Therapy, 31(7), 2266-2285. https://doi.org/10.1016/j.ymthe.2023.03.014
Vancouver
Rojo-Romanos T, Karpinski J, Millen S, Beschorner N, Simon F, Paszkowski-Rogacz M, et al. Precise excision of HTLV-1 provirus with a designer-recombinase. Molecular Therapy. 2023;31(7):2266-2285. doi:10.1016/j.ymthe.2023.03.014
BibTeX
@article{RojoRomanos2023,
author = {Rojo-Romanos, Teresa and Karpinski, Janet and Millen, Sebastian and Beschorner, Niklas and Simon, Florian and Paszkowski-Rogacz, Maciej and Lansing, Felix and Schneider, Paul Martin and Sonntag, Jan and Hauber, Joachim and Thoma-Kress, Andrea K and Buchholz, Frank},
title = {Precise excision of HTLV-1 provirus with a designer-recombinase},
journal = {Molecular Therapy},
year = {2023},
volume = {31},
number = {7},
pages = {2266--2285},
doi = {10.1016/j.ymthe.2023.03.014}
}
EUVIMED